InvestSMART

Neuren Pharmaceuticals Limited (ASX:NEU)

ALERT: Price-sensitive ASX Announcement for NEU
Current share price for NEU : $20.450 7.74 (60.90%)+
Announcement
Release
26 Feb 2026 11:15AM
Price at Release
$12.710
Full Release
download
Summary
Neuren Pharmaceuticals Limited announced that its partner, Acadia Pharmaceuticals, reported DAYBUE net sales of US$391 million for 2025, a 12% increase from the previous year. In Q4 2025 alone, net sales were US$110 million, marking a 13% growth compared to the same quarter in 2024. Neuren's royalty income from DAYBUE also increased to A$65 million for the full year 2025. Looking ahead, Acadia's 2026 net sales guidance for DAYBUE is set between US$460 million and US$490 million, suggesting Neuren's royalty income could reach between A$70 million and A$77 million. Additionally, DAYBUE STIX, a new powder formulation, received FDA approval in late 2025, with broader availability anticipated by Q2 2026. Trofinetide is also undergoing Phase 3 trials in Japan, with results expected by early 2027.
Key Points
  • Acadia reported full year 2025 DAYBUE net sales of US$391 million, up 12% year-on-year.
  • Q4 2025 DAYBUE net sales reached US$110 million, a 13% increase compared to Q4 2024.
  • Neuren’s full year 2025 royalty income was A$65 million, a 15% increase from 2024.
  • Acadia’s guidance for full year 2026 DAYBUE net sales is US$460 million to US$490 million.
  • Neuren expects full year 2026 royalty income of A$70 million to A$77 million from DAYBUE.
  • DAYBUE STIX powder formulation was approved in December 2025, with a full launch expected by Q2 2026.
  • Phase 3 clinical trial of trofinetide ongoing in Japan with results expected between Q4 2026 and Q1 2027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.